EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Thymic epithelial tumor medical treatment: A narrative review

Qian Huang, Lingling Zhu, Yanyang Liu, Yan Zhang

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024

DOI: 10.1016/j.bbcan.2024.189167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Qian Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Lung Cancer Center/Lung Cancer Institute, Wes…. Hauptthemen laut MEDLINE: Thymus Neoplasms, Neoplasms, Glandular and Epithelial, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thymic epithelial tumors, a malignancy originating in the thymus, are the commonest primary neoplasm of the anterior mediastinum; however, among thoracic tumors, they have a relatively low incidence rare. Thymic epithelial tumors can be broadly classified into thymic carcinoma and thymoma. As the cornerstone of thymic tumor treatment, surgery is the preferred treatment for early-stage patients, whereas, for advanced unresectable thymic tumors, the treatment is chemoradiotherapy. Targeted therapy is less effective for thymic tumors. Moreover, the use of immune checkpoint inhibitors as another effective treatment option for advanced unresectable thymic tumors, particularly thymomas, is limited owing to immune-related adverse effects. Here, we have summarized all pertinent information regarding chemotherapy, especially preoperative neoadjuvant chemotherapy, and chemotherapy in combination with other treatments, and reviewed the effectiveness of these procedures and recent advances in targeted therapy. In addition, we analyzed the efficacy and safety of immune checkpoint inhibitors in thymic epithelial tumors, to provide a holistic treatment view.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymus NeoplasmsNeoplasms, Glandular and EpithelialImmune Checkpoint InhibitorsHumansThymomaNeoadjuvant Therapy

Stichwörter der Autor:innen

ChemotherapyImmunotherapyTargeted therapyThymic epithelial tumor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China. Electronic addre…

Zitieren

APA

Huang, Q., Zhu, L., Liu, Y., & Zhang, Y. (2024). Thymic epithelial tumor medical treatment: A narrative review. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189167

Vancouver

Huang Q, Zhu L, Liu Y, Zhang Y. Thymic epithelial tumor medical treatment: A narrative review. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189167

BibTeX
@article{Huang2024,
  author = {Huang, Qian and Zhu, Lingling and Liu, Yanyang and Zhang, Yan},
  title = {Thymic epithelial tumor medical treatment: A narrative review},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  doi = {10.1016/j.bbcan.2024.189167}
}
Kostenlos starten →